Pancrelipase

Pancreatic enzyme replacement Digestive enzyme

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO (oral) 1-2 teaspoons (or 1-2 g) of powder per meal; or 10,000-20,000 units of lipase per meal (adjust based on response) With each meal (usually 2-3 times daily) Duration: Lifelong therapy
Notes: Powder is preferred over capsules for better mixing with food. Administer with meals; do not mix with hot food (enzymes are heat-labile). Start with a standard dose and adjust based on clinical response (stool quality, weight gain).
Cat PO (oral) 1/4 to 1/2 teaspoon of powder per meal; or 5,000-10,000 units of lipase per meal With each meal Duration: Lifelong therapy
Notes: Cats may require lower doses; adjust based on response. Mix with food just before feeding.
Horse PO (oral) Not well established; typically 1-2 scoops (per manufacturer) mixed with feed With each meal Duration: As needed
Notes: Off-label use; limited evidence. Consult a veterinary nutritionist.

Clinical Indications & Species Uses

General Indications
  • Exocrine pancreatic insufficiency (EPI) in dogs and cats
Dog (Canine)
  • Exocrine pancreatic insufficiency (EPI)
Cat (Feline)
  • Exocrine pancreatic insufficiency (EPI) (less common)

Pharmacology & Mechanism of Action

Drug Class: Pancreatic enzyme replacement | Pharmacological Group: Digestive enzyme

Mechanism of Action: Pancrelipase is a combination of pancreatic enzymes (lipase, amylase, and protease) derived from porcine pancreas. It replaces endogenous pancreatic enzymes that are deficient due to exocrine pancreatic insufficiency (EPI). Lipase hydrolyzes triglycerides into monoglycerides and free fatty acids; amylase breaks down starches into dextrins and short-chain sugars; proteases (trypsin and chymotrypsin) cleave proteins into peptides and amino acids. This facilitates normal digestion and absorption of fats, carbohydrates, and proteins.

Pharmacodynamics: The enzymes act locally in the gastrointestinal tract. Lipase is the most critical component for managing steatorrhea. The activity is pH-dependent; lipase is inactivated at pH <4, so enteric-coated formulations protect the enzymes until they reach the duodenum. The therapeutic goal is to reduce steatorrhea, improve nutrient absorption, and normalize stool consistency and body weight.

⚑ Pharmacokinetics Summary

Absorption: Pancrelipase is not absorbed systemically to a significant extent; it acts locally within the gastrointestinal lumen. No meaningful systemic absorption occurs.
Distribution: Not applicable; the enzymes remain in the gastrointestinal tract and are excreted in feces.
Metabolism: The enzymes are proteins and are digested by proteolytic enzymes in the intestine; they are not metabolized by hepatic pathways.
Excretion: The enzymes are excreted in feces, either intact or as digested peptides.
Half-Life: Not applicable (local action, no systemic half-life).
Bioavailability: Not applicable; acts locally.
Protein Binding: Not applicable.

Available Formulations & Strengths

Oral Powder Typically contains lipase 16,800-24,000 units, amylase 70,000-100,000 units, protease 70,000-100,000 units per gram (varies by brand) (PO)
Oral Capsule (enteric-coated) Various strengths (e.g., lipase 5,000; 10,000; 20,000 units per capsule) (PO)
Oral Tablet (enteric-coated) Various strengths (e.g., lipase 10,000; 20,000 units per tablet) (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to porcine proteins
  • Acute pancreatitis or acute flare of chronic pancreatitis (relative contraindication; use with caution)
  • Known allergy to any component of the formulation
Warnings & Clinical Precautions:
  • Do not inhale powder; it can cause bronchospasm or allergic reactions in handlers.
  • Avoid contact with skin and eyes; wash hands after handling.
  • Do not crush or chew enteric-coated tablets/capsules; they should be swallowed whole.
  • Do not mix with hot foods or alkaline solutions; enzymes are inactivated.
  • Use with caution in patients with gout, hyperuricemia, or renal impairment (may increase uric acid levels).
  • In patients with cystic fibrosis (rare in animals), high doses may cause fibrosing colonopathy.
  • Monitor for adequate nutritional status and weight gain.

Adverse Effects & Reactions

Common:

  • Gastrointestinal upset (nausea, vomiting, diarrhea)
  • Perioral irritation (if powder contacts skin)
  • Mild hyperuricemia

Serious / Severe:

  • Allergic reactions (anaphylaxis, bronchospasm)
  • Fibrosing colonopathy (with very high doses, especially in cystic fibrosis)
  • Intestinal obstruction (rare, with large doses)

Rare:

  • Oral mucosal ulceration (if powder held in mouth)
  • Hyperuricosuria and uric acid stones

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Antacids (calcium carbonate, magnesium hydroxide) May reduce enzyme activity by raising gastric pH and affecting enteric coating; separate administration by at least 1 hour. Moderate
Iron supplements Pancrelipase may reduce iron absorption; separate administration. Mild
Folate Pancrelipase may reduce folate absorption; monitor folate levels. Mild
Acarbose Potential additive hypoglycemic effect if used concurrently (rare in veterinary medicine). Mild

Overdose & Toxicity Management

Signs of Toxicity:

  • Hyperuricemia
  • Hyperuricosuria
  • Gastrointestinal upset (vomiting, diarrhea)
  • Perianal irritation
  • In severe cases: intestinal obstruction, fibrosing colonopathy

Emergency Treatment Protocol: Discontinue the drug and provide supportive care. Monitor serum uric acid and renal function. Treat dehydration and electrolyte imbalances if present. In cases of suspected intestinal obstruction, perform imaging and surgical intervention if necessary.

Food Animal Withdrawal Times

πŸ₯© Meat: 0 daysπŸ₯› Milk: 0 daysπŸ₯š Eggs: 0 days

Not approved for food animals; no withdrawal times established. Use in food animals is off-label and should follow veterinary supervision and FARAD recommendations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25Β°C) in a dry place; avoid excessive heat and moisture.

Handling & Special Conditions: Keep container tightly closed. Do not refrigerate. Protect from moisture.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; available as human prescription products used off-label in animals.

Extra-Label (Off-Label) Use: In the US, pancreatic enzyme products are FDA-approved for human use but not specifically for veterinary use. Use in animals is extra-label and must comply with AMDUCA regulations. For food animals, extra-label use requires a valid veterinarian-client-patient relationship and extended withdrawal times may be necessary.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Pancrelipase is the mainstay of treatment for exocrine pancreatic insufficiency (EPI) in dogs and cats. The powder formulation is generally preferred over capsules because it can be mixed thoroughly with food and allows easier dose adjustment. The dose should be individualized based on clinical response (stool quality, weight gain, resolution of steatorrhea). It is important to feed a highly digestible, low-fiber diet and to avoid adding enzymes to hot food. Concurrent supplementation with cobalamin (vitamin B12) and folate may be necessary due to malabsorption. Regular monitoring of body weight, serum cobalamin, and clinical signs is recommended. In some cases, additional therapy with antacids or H2 blockers may be considered to reduce gastric acid inactivation of enzymes, but this is not routinely required. Owners should be educated on proper handling to avoid inhalation of powder.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)